ReviewInternational journal of nanomedicine2026
PEGylated PLGA Nanoformulations For Effective Immunomodulatory Actors In Non-Small Cell Lung Cancer.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles have attracted increasing attention as a versatile and biocompatible nanoplatform for non-small cell lung cancer (NSCLC) therapy. Benefiting from prolonged circulation time, controllable drug-release behavior, and flexible surface modification, PEG-PLGA nanocarriers can effectively enhance tumor accumulation while reducing systemic toxicity. Recent advances indicate that PEG-PLGA nanoparticles not only improve the delivery efficiency of chemotherapeutic agents but also enable active tumor targeting through ligand conjugation and contribute to the regulation of the tumor immune microenvironment. In particular, these nanoplatforms have shown promising potential in enhancing antigen presentation, alleviating immunosuppression, and synergizing with immunotherapeutic strategies such as immune checkpoint blockade. Nevertheless, several challenges remain for clinical translation, including large-scale manufacturing, formulation reproducibility, and regulatory considerations. Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.